Total medical devices industry deals worth $8.1bn were announced globally for May 2021, with the $1.36bn acquisition of Vectura Group being the sector’s biggest investment, according to GlobalData’s deals database.
Go deeper with GlobalData
- Embed this chart
Embed this chart into your website
Copy and paste the image source into your website to display the chart.
The value marked an increase of 6.8% over the previous month of $7.56bn and a drop of 6.3% when compared with the last 12-month average of $8.61bn.
In terms of number of deals, the sector saw a drop of 10.30% with 148 deals in May 2021 when compared to the last 12-month average of 165 deals.
In value terms, North America led the activity with deals worth $4.61bn in May 2021.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataMedical Devices industry deals in May 2021: Top deals
The top five deals accounted for 45.4% of the overall value during May 2021.
The combined value of the top five deals stood at $3.67bn, against the overall value of $8.1bn recorded for the month.
The top five medical devices industry deals of May 2021 tracked by GlobalData were:
1) Murano Bidco’s $1.36bn acquisition of Vectura Group
2) The $830m private equity deal with Caris Life Sciences by L.P, Canada Pension Plan Investment Board, ClearBridge Investments, Coatue Management, Columbia Threadneedle Investments, Eaton Vance, Fidelity Management & Research, First Light Asset Management, Highland Capital Management, Millennium Management, Orbimed Advisors, Pura Vida Investments, Rock Springs Capital Management, Silver Lake Management, T Rowe Price Associates, TPG Sixth Street Partners and Tudor Investment
3) Allergan Aesthetics’ $550m acquisition of Soliton
4) The $540m venture financing deal of Noom by Novo Holdings, Oak HC/FT Partners, RRE Ventures, Samsung Ventures Investment, Sequoia Capital Operations, Silver Lake Management and Temasek Holdings (Private)
5) NeoGenomics’ acquisition deal with Inivata for $390m.
